management intervention had no major effect on RA disease activity metrics over the 24-month follow-up. However, patients in the intervention arm reported a positive effect of the intervention. More studies are needed to further understand patient preferences for optimal RA flare management and to design interventions to meaningfully address these preferences.

REFERENCE:

[1] Bechman, K., et al. *J Rheumatol*, 2018. **45**(11): p. 1515-21.

Disclosure of Interests: Elena Myasoedova Grant/research support from: Pfizer, Cynthia S. Crowson: None declared, Rachel Giblon: None declared, Daniel Schaffer: None declared, Kerry Wright: None declared, Eric Matteson Grant/research support from: Eric Matteson has received research grants from Pfizer and Sun Pharmaceutical Industries, Ltd. for work on the pathobiology of rheumatoid arthritis., Consultant for: Eric Matteson has received consultancy fees from Boehringer Ingelheim for an advisory board., John Davis Grant/research support from: Pfizer

DOI: 10.1136/annrheumdis-2019-eular.2477

OP0310

IMPLEMENTATION OF TNF-BIOSIMILARS (INFLIXIMAB AND ETANERCEPT) IN DANISH DEPARTMENTS OF RHEUMATOLOGY

Thomas Bo Jensen¹, Dorte Bartels², Eva Aggerholm Sædder³, Birgitte Klindt Poulsen⁴, Stig Ejdrup Andersen⁵, Mette Marie H. Christensen⁶, Lars Nielsen⁷, Hanne Rolighed Christensen¹. ¹Copenhagen University Hospital Bispebjerg, Department of Clinical Pharmacology, Copenhagen, Denmark; ²Amgros – The Regions' Pharmaceutical Organisation, Copenhagen, Denmark; ³Aarhus University Hospital, Department of Clinical Pharmacology, Aarhus, Denmark; ⁴Aalborg University Hospital, Department of Clinical Pharmacology, Aalborg, Denmark; ⁵Zealand University Hospital, Clinical Pharmacology Unit, Roskilde, Denmark; ⁶Odense University Hospital, Department of Clinical Biochemistry and Pharmacology, Odense, Denmark; ⁷The Hospital Pharmacy of The Capital Region of Denmark, Herlev, Denmark

Background: The use of expensive biological drugs in rheumatology is rapidly increasing and has led to substantial increases in drug expenditures. A considerable reduction of drug costs is possible by using biosimilars as soon as they become available and carrying out non-medical shifts to biosimilars (i.e. switching a patient well treated on a biooriginator to the biosimilar). Research on biosimilars has focused on interchangeability and safety outcomes, but little focus has been on nationwide implementation and the direct economic consequences on drug expenses.

In Denmark, TNF-inhibitors are solely given in an in-hospital setting and bought through national tenders. The Danish in-hospital organization includes Regional Drug and Therapeutics Committees that ensures regional implementation of treatment guidelines and close collaboration between hospital pharmacies and regional clinical pharmacologists. Furthermore, the implementation of TNF-inhibitor biosimilars was preceded by careful preparations from among others a newly established national biosimilar task force.

Objectives: The aim of this study was to describe the implementation of the two first TNF-inhibitor biosimilars (infliximab and etanercept) in Danish departments of rheumatology.

Methods: Monthly data on drug sales to Danish rheumatology departments were used to assess the biosimilar uptake rate and subsequent changes in the drug expenditures during the implementation in Denmark.

Results: Shifts to biosimilars were begun within a few months following end of biooriginator patent, vertical lines in the figure. Use of the infliximab biosimilar was begun in April 2015, and in August 2015 biosimilar uptake was 92.9% of total infliximab use. Similarly use of etanercept biosimilar was begun in April 2016, and in June 2016 the biosimilar uptake was 91.6% of total etanercept use. In January 2015 the total use in Defined Daily Doses (DDD) were 42.4 thousand DDD's for infliximab and 37.3 thousand DDD's for etanercept. The use increased steadily and was in January 2018 138.4 thousand DDD's for infliximab and 62.1 thousand DDD's for etanercept (equivalent to increases of 226.6% and 66.8%). The increases in DDD's were not reflected in total drug costs due to the shift to biosimilars. The total drug cost for infliximab in January 2015 was 6.7 million DKK but was reduced to 5.4 million DKK in January 2018 (-19.4%). A corresponding cost reduction was seen for etanercept (11.3 million DKK in January 2015, 8.1 million DKK in January 2018, -28.7%).

Conclusion: Danish departments of rheumatology experienced a fast and near-complete switch of infliximab and etanercept biooriginators to biosimilars. At the same time the use of the drugs increased substantially, but due to large price reductions the total drug cost decreased despite the increasing use. We believe that a thorough preparation and an organizational setting supporting the implementation was crucial for the successful implementation. The Danish structure, with its national tendering, probably contributed to the substantial drug discounts obtained. The implementation will be used for future biosimilars in Denmark.

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2019-eular.1383

OP0311

RETROSPECTIVE ANALYSIS OF PRESCRIPTION DYNAMICS OF ETANERCEPT AFTER INTRODUCTION OF BIOSIMILARS BASED ON NORWEGIAN PRESCRIPTION DATABASE. AN INTERIM ANALYSIS

Milada Cvancarova Småstuen¹, Randeep Madla², Oddvar Solli³, Erik Hjelvin². ¹Nursing Science, Public Health, Oslo, Norway; ²Pfizer, Oslo, Norway; ³Pfizer, Oslo, Norway

Background: In Norway, several high quality data registries are available that can be used to generate "real life" data. All individuals living in Norway are given a unique ID number which makes it possible to trace individuals. The Norwegian Prescription Database (NorPD) is one of the central public registers that are available for research purposes. All prescriptions being collected by individuals are recorded, including reimbursement code, dispensing date, name and dose of the prescribed drug. Following loss of exclusivity of some biologics, biosimilars are competing in the Norwegian tender.

Objectives: Both efficacy, bio-chemical features and patient satisfaction with biosimilars have been debated since they were introduced to replace originator. However, there is only sparse evidence as to how many patients were switched and how many are switched back to the originator so large, registry based studies are warranted.

Therefore, our aim was to follow all patients on originator receiving maintenance treatment (drug prescription being collected and registered in NorPD) after biosimilar entry (BE) in order to retrospectively describe the pattern of switch and monitor dynamics, assumed to be economically motivated from patients stable on originator to biosimilars or other preferred drug.

Methods: We included all patients on etanercept maintenance treatment for 9 months prior to BE with maximum gap of 4 months from previous prescription retrieval. Switch was defined as discontinuation of use for at least 4 consecutive months.

Prescription data scans from NorPD started March 2016 (BE) and data scans were performed every 3 months during the first 6 months of this project and every 6 months for 2 years. Final data extraction will be performed within July 2019. This abstract covers the interim analysis and the time period from 9 months prior to BE and 18 months thereafter.

Results: We have identified 8149 individuals on biologics prescribed in Norway. Of those, 4799 collected at least two prescriptions of etanercept before BE and are included in further analyses. The proportion of originator etanercept users declined sharply after biosimilar entry as expected for the first three months after BE and kept decreasing for the consecutive 9 months, however it changed little thereafter.

A great majority of former etanercept users was switched to SB4 (70.5%) and continued with this medication, however some switched back to etanercept or other